| |
Which insulins do you or your child use? |
|
| |
Vote for all that apply |
|
| |
Short acting insulins |
|
| |
|
|
NovoLog / Novorapid |
|
| |
42% |
|
 101 |
|
| |
|
|
Humalog |
|
| |
18% |
|
43 |
|
| |
|
|
Apidra |
|
| |
9% |
|
21 |
|
| |
|
|
Regular / Actrapid / Velosulin |
|
| |
1% |
|
3 |
|
| |
|
|
Other short acting insulin |
|
| |
0% |
|
0 |
|
| |
Long acting insulins |
|
| |
|
|
Lantus |
|
| |
21% |
|
50 |
|
| |
|
|
Levemir |
|
| |
4% |
|
10 |
|
| |
|
|
NPH / Isophane / Insulatard |
|
| |
3% |
|
8 |
|
| |
|
|
Other long acting insulin |
|
| |
1% |
|
2 |
|
| |
Other |
|
| |
|
|
Premixed (70/30, etc.) |
|
| |
1% |
|
2 |
|
| |
|
|
Other insulin |
|
| |
0% |
|
0 |
|
Total votes: 240 |
|
|
|
|
Which insulins do you or your child use?
Poll dates: January 18 - 25, 2012
Total Votes: 240
Insulin users today have a great variety of products from which to choose. Fast-acting analogs (Humalog, NovoLog, and Apidra) and long-acting analogs (Lantus and Levemir) have changed the way many people use insulin. The use of Regular insulin among our readers has dropped off to just one percent. NPH use has dropped too, from 32% in 2000 to just 3% today.
This table shows readers' answers to this survey over the past years:
| Short acting insulins |
| NovoLog |
42% |
40% |
40% |
38% |
35% |
33% |
28% |
27% |
26% |
12% |
3% |
-- |
| Humalog |
18% |
17% |
21% |
18% |
19% |
17% |
20% |
22% |
26% |
34% |
37% |
35% |
| Apidra |
9% |
5% |
4% |
5% |
1% |
1% |
1% |
1% |
-- |
-- |
-- |
-- |
| Regular/Other |
1% |
1% |
1% |
1% |
1% |
1% |
1% |
1% |
2% |
3% |
4% |
12% |
| Long acting insulins |
| Lantus |
21% |
24% |
23% |
28% |
30% |
31% |
32% |
27% |
21% |
17% |
11% |
-- |
| Levemir |
4% |
6% |
3% |
4% |
4% |
4% |
2% |
1% |
-- |
-- |
-- |
-- |
| NPH |
3% |
4% |
4% |
5% |
3% |
6% |
8% |
14% |
16% |
22% |
28% |
32% |
| Other |
1% |
0% |
0% |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
-- |
| Lente |
-- |
-- |
-- |
-- |
0% |
1% |
1% |
1% |
1% |
1% |
3% |
4% |
| Ultralente |
-- |
-- |
-- |
-- |
1% |
1% |
1% |
1% |
1% |
2% |
5% |
7% |
| Other |
| Premixed |
1% |
0% |
1% |
1% |
1% |
1% |
1% |
1% |
1% |
2% |
2% |
5% |
| Other insulin |
0% |
1% |
1% |
1% |
2% |
1% |
1% |
1% |
1% |
2% |
2% |
2% |
Percentages based on use compared with all responses
Looking at answers in the short-acting and long-acting insulins shows a dramatic change since 2000. The following graphs illustrate the rapid increase in use of insulin analogs and the concurrent decline in the use of Regular and NPH.
Rapid Acting Insulin Use
The rise in the use of NovoLog has been particularly significant since it was introduced in 2002. Among users of rapid-acting insulin, NovoLog is used by almost two-thirds of our visitors (60%), while about one-fourth (26%) use Humalog and 13% use Apidra. The use of Regular continues to decline and is now at a reported 2%.
Data within rapid-acting insulin only
Data for rapid-acting insulin among all responses
Long Acting Insulin Use
As of January 2012, more CWD visitors report using Lantus than any other long acting insulin by a wide margin. This year, 74% of people who use long acting insulin report using Lantus. The use of NPH continues to decline and and now stands at 12% for people who use long acting insulin. Levemir, new in 2005, is used by 15%. Given the clinical benefits of using Lantus or Levemir over NPH, it's no surprise to see the rapid decline in use of NPH. (See our page about Care Suggestions for citations to studies about NPH.)
Data for long-acting insulin only
Data for long-acting insulin among all responses
[Download an Excel 2007/2010 spreadsheet with the data and graphs from this poll]
[Return to the current poll]
|
This site is published by Children With Diabetes, Inc, which is responsible for its contents.